PlumX Metrics
Embed PlumX Metrics

Pipeline for characterizing alternative mechanisms (PCAM) based on bi-clustering to study colorectal cancer heterogeneity

Computational and Structural Biotechnology Journal, ISSN: 2001-0370, Vol: 21, Page: 2160-2171
2023
  • 1
    Citations
  • 0
    Usage
  • 4
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    1
    • Citation Indexes
      1
      • CrossRef
        1
  • Captures
    4
  • Mentions
    1
    • News Mentions
      1
      • News
        1

Most Recent News

New Personalized Medicine Data Have Been Reported by Researchers at Indiana University [Pipeline for characterizing alternative mechanisms (PCAM) based on bi-clustering to study colorectal cancer heterogeneity]

2023 APR 07 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Investigators publish new report on personalized medicine. According to news

Article Description

The cells of colorectal cancer (CRC) in their microenvironment experience constant stress, leading to dysregulated activity in the tumor niche. As a result, cancer cells acquire alternative pathways in response to the changing microenvironment, posing significant challenges for the design of effective cancer treatment strategies. While computational studies on high-throughput omics data have advanced our understanding of CRC subtypes, characterizing the heterogeneity of this disease remains remarkably complex. Here, we present a novel computational Pipeline for Characterizing Alternative Mechanisms (PCAM) based on biclustering to gain a more detailed understanding of cancer heterogeneity. Our application of PCAM to large-scale CRC transcriptomics datasets suggests that PCAM can generate a wealth of information leading to new biological understanding and predictive markers of alternative mechanisms. Our key findings include: 1) A comprehensive collection of alternative pathways in CRC, associated with biological and clinical factors. 2) Full annotation of detected alternative mechanisms, including their enrichment in known pathways and associations with various clinical outcomes. 3) A mechanistic relationship between known clinical subtypes and outcomes on a consensus map, visualized by the presence of alternative mechanisms. 4) Several potential novel alternative drug resistance mechanisms for Oxaliplatin, 5-Fluorouracil, and FOLFOX, some of which were validated on independent datasets. We believe that gaining a deeper understanding of alternative mechanisms is a critical step towards characterizing the heterogeneity of CRC. The hypotheses generated by PCAM, along with the comprehensive collection of biologically and clinically associated alternative pathways in CRC, could provide valuable insights into the underlying mechanisms driving cancer progression and drug resistance, which could aid in the development of more effective cancer therapies and guide experimental design towards more targeted and personalized treatment strategies. The computational pipeline of PCAM is available in GitHub (https://github.com/changwn/BC-CRC).

Bibliographic Details

Cao, Sha; Chang, Wennan; Wan, Changlin; Lu, Xiaoyu; Dang, Pengtao; Zhou, Xinyu; Zhu, Haiqi; Chen, Jian; Li, Bo; Zang, Yong; Wang, Yijie; Zhang, Chi

Elsevier BV

Biochemistry, Genetics and Molecular Biology; Computer Science

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know